Detail akcie Oramed online

Business Summary: Oramed Pharmaceuticals Inc. is a pharmaceutical company, which is engaged in the research and development of pharmaceutical solutions with its technology platform. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. It is conducting Phase III trials in patients with type 2 diabetes. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. It is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary, Oravax Medical Inc.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Oramed Pharmaceuticals, Inc. revenues decreased 50% to $1.3M. Net income totaled $5.5M vs. loss of $36.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects RESEARCH AND DEVELOPMENT EXPENSES decrease of 68% to $9M (expense), GENERAL AND ADMINISTRATIVE EXPENSES decrease of 39% to $8.4M (expense).